Remarkably, we have provided the first line of evidence demonstrating that YTHDF2 is a tumor promoter in ovarian cancer, because ablation of YTHDF2 dampens cell proliferation and enhances apoptosis (Fig. 5), which recapitulates the tumor phenotype in vitro and in vivo caused by FBW7 overexpression (Fig. 2). This evidence concerns the gene FBXW7 and neoplasm.